GAITHERSBURG, Md.–(BUSINESS WIRE)–Sigma-Tau Pharmaceuticals, Inc., today announced that its Board of
Directors has appointed Michael Minarich as the Company’s Chief
Executive Officer (CEO), effective July 13, 2016. Mr. Minarich has
served as interim Chief Executive Officer of the company since July 2015.
Prior to joining Sigma-Tau Pharmaceuticals in 2015, Mr. Minarich was
providing consulting services to start-ups and early- and mid-stage
companies in the biosciences and specialty pharmaceutical industries. He
spent the previous 20 years as an expatriate in Asia (Seoul), Canada
(Montreal) and Europe (Brussels & Prague) as the Market Company
President, Czech Republic for Pharmacia Corporation and at legacy
company, G.D. Searle / Monsanto, with increasing responsibilities in
international General Management, Marketing and Business Development.
“We are delighted to appoint Mike to the position of Chief Executive
Officer of Sigma-Tau Pharmaceuticals, Inc.,” said Marco Brughera, CEO
and Global Head of Rare Disease at Sigma-Tau Rare Disease Ltd. “Mr.
Minarich has demonstrated outstanding leadership over the past year, and
his appointment comes at a time of development in the company, as it
expands through registration, life-cycle management and
commercialization of its proprietary R&D pipeline. The appointment of
the Chief Executive role reflects the commitment Sigma-Tau has to the
field of rare diseases, and to the significant impact we expect these
medicines will ultimately have on their respective physician and patient
About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary
of the Essetifin Group, and is dedicated to the global development and
commercialization of medicines for patients with rare diseases.
Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Maryland.
Since 1989, the company’s products have been focused on kidney disease,
certain genetic disorders and cancers. With more than 7,000 identified
rare diseases that affect approximately 30 million patients in the U.S.
alone, Sigma-Tau places its considerable scientific resources behind the
development and commercialization of compounds that benefit the few. For
more information about the company, visit www.sigmatau.com.
Sigma-Tau Pharmaceuticals, Inc.
David Sandoval, 301-948-1041
Director, Legal Affairs & Compliance
LLC on behalf of Sigma-Tau Pharmaceuticals, Inc.
973-442-1555 ext. 102